Rolvedon Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing use of chemotherapy regimens, rising incidence of treatment-induced neutropenia, clinical acceptance of colony-stimulating factors, expansion of oncology treatment centers, established supportive care guidelines.

The growth in the forecast period can be attributed to increasing demand for patient-friendly oncology supportive drugs, rising focus on treatment adherence improvement, expansion of outpatient cancer care, growing investments in long-acting biologics, continued development of differentiated g-csf formulations. Major trends in the forecast period include increasing adoption of long-acting g-csf therapies, rising focus on infection risk reduction during chemotherapy, growing preference for reduced dosing frequency treatments, expansion of supportive oncology care protocols, enhanced monitoring of neutrophil recovery.

The increasing prevalence of cancer is expected to drive the growth of the rolvedon market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can form tumors, invade surrounding tissues, and metastasize to other parts of the body. The rise in cancer prevalence is attributed to factors such as aging populations, lifestyle choices, environmental exposures, genetic predisposition, and improvements in diagnostic techniques. Rolvedon supports cancer patients by stimulating white blood cell production, specifically increasing neutrophil counts, to reduce the risk of infection during chemotherapy and bolster the immune system. For instance, in November 2024, according to PubMed, a US-based federal government research and information organization, the number of cancer cases worldwide is projected to reach 35.3 million by 2050, a 76.6% increase from the 2022 estimate of 20 million. Therefore, the increasing prevalence of cancer is driving the growth of the rolvedon market.

Major companies operating in the Rolvedon market are focusing on developing innovative solutions, such as biologic medications, to meet the growing demand for targeted, personalized, and effective treatments with fewer side effects. Biologic medications are advanced therapies derived from living cells, such as proteins or antibodies, offering greater precision in treating complex conditions compared to traditional small-molecule drugs. For instance, in April 2023, Spectrum Pharmaceuticals, Inc., a US-based biopharmaceutical company, achieved a significant commercial milestone for Rolvedon (eflapegrastim-xnst), a next-generation biologic therapy used in oncology care. Rolvedon is designed to reduce the incidence of infection, particularly febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Its long-acting recombinant G-CSF formulation enhances neutrophil recovery, improves chemotherapy tolerance, and provides a more predictable therapeutic profile. The assignment of a permanent J-code (J1449) by CMS facilitates streamlined reimbursement, supports wider clinical adoption, and positions the product to access a potential $2 billion market opportunity.

In April 2023, Assertio Holdings Inc., a US-based pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. for an undisclosed amount. This acquisition allows Assertio Holdings, Inc. to strengthen its oncology portfolio, accelerate revenue growth, and improve market access through strategic integration and operational efficiencies. Spectrum Pharmaceuticals, Inc. develops Rolvedon for chemotherapy-induced neutropenia, providing targeted support for patients undergoing cancer treatment.

Major companies operating in the rolvedon market are Hanmi Pharm Co Ltd.

North America was the largest region in the rolvedon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rolvedon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rolvedon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the rolvedon market by increasing costs associated with imported biologic drug substances, specialized fill-finish equipment, prefilled syringe components, and temperature-controlled packaging materials. Oncology drug manufacturers in North America and Europe are most affected due to dependence on international biologics supply chains, while Asia-Pacific experiences cost pressure on contract manufacturing services. These tariffs are raising production and distribution expenses, impacting pricing strategies for supportive cancer therapies. However, they are also encouraging localized biologics manufacturing, regional supply chain integration, and investments in domestic sterile injectable capabilities.

The rolvedon market research report is one of a series of new reports that provides rolvedon market statistics, including rolvedon industry global market size, regional shares, competitors with a rolvedon market share, detailed rolvedon market segments, market trends and opportunities, and any further data you may need to thrive in the rolvedon industry. This rolvedon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rolvedon is a medication used to lower the risk of infection in cancer patients receiving chemotherapy. It is a long-acting granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells, particularly neutrophils, which are essential for fighting infections.

The primary clinical indications for Rolvedon include the main medical condition or disease it is approved to treat, the target patient population, and the treatment context. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, specialty centers, homecare settings, and research and academic institutions.

The rovedon market consists of sales of syringes and injection devices, biologic drugs for neutropenia, diagnostic and monitoring equipment, oncology care kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.